{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.949","value":"19.33"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"278"}],"units":"Participants"}],"title":"Disease Symptoms: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.857","value":"11.11"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"Disease Symptoms: End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.903","value":"17.80"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"278"}],"units":"Participants"}],"title":"Side-Effects of Treatment: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.857","value":"16.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"Side-Effects of Treatment: End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.397","value":"28.18"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"278"}],"units":"Participants"}],"title":"Body Image: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.570","value":"16.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"Body Image: End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.634","value":"42.49"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"278"}],"units":"Participants"}],"title":"Future Perspective: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.000","value":"33.33"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"Future Perspective: End of Treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"278"}],"units":"Participants"}],"description":"EORTC QLQ-MY20 has 20 items across 4 independent subscales, 2 functional subscales (body image, future perspective), and 2 symptoms scales (disease symptoms, and side effects of treatment). Scores are averaged, and transformed to 0-100 scale. For the future perspective scale, higher score = better perspective of the future. For the body image scale, higher scores = better body image. Higher score for the disease symptoms scale = higher level of symptomatology.","dispersionType":"Standard Deviation","groups":[{"description":"Participants took ixazomib, lenalidomide, and dexamethasone under conditions of standard medical care in this study. The dosage and administration of ixazomib, lenalidomide, and dexamethasone were not defined by the protocol but according to the package insert of each drug.","id":"OG000","title":"Ixazomib + Lenalidomide + Dexamethasone"}],"paramType":"MEAN","populationDescription":"Full Analysis Set, defined as all participants who were enrolled into the study and who receive at least one dose of ixazomib.","reportingStatus":"POSTED","timeFrame":"Baseline and End of Treatment (Up to 37 cycles, each cycle was of 28 days)","title":"Patient-Reported Outcome HRQoL Based on EORTC Multiple Myeloma Module (EORTC QLQ-MY20) Score","type":"SECONDARY","unitOfMeasure":"Score on a Scale"}